Supplements
. Decision curve analysis for different prediction models incorporating prostate measurements in 3616 patients from ERSPC. Table S1 . Clinical impact of the three prostate cancer risk calculators.
A: Absolute number of biopsy reduction per 1000 B: Absolute number of missed PCa GS ≥3+4 per 1000 (% of total PCa GS ≥3+4) C: Absolute number of missed indolent PCa per 1000 (% missed of total indolent PCa) D: Net benefit x 1000; ΔD: Additional net true positives per 1000 men compared with reference strategy E: Net reduction of biopsies per 1000 men, compared to the reference strategy (biopsy is advised when PSA >3.0ng/ml); formula: ΔNB/(threshold/(1-threshold))*1000. 
